Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial 

Published byEugene Arnold Jenkins Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial "— Presentation transcript:

1 Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial  Patrick M. Moriarty, MD, Paul D. Thompson, MD, Christopher P. Cannon, MD, John R. Guyton, MD, Jean Bergeron, MD, Franklin J. Zieve, MD, PhD, Eric Bruckert, MD, Terry A. Jacobson, MD, Stephen L. Kopecky, MD, Marie T. Baccara-Dinet, MD, Yunling Du, PhD, Robert Pordy, MD, Daniel A. Gipe, MD  Journal of Clinical Lipidology  Volume 9, Issue 6, Pages (November 2015) DOI: /j.jacl Copyright © 2015 National Lipid Association Terms and Conditions

2 Figure 1 Flow chart. ITT, intent-to-treat.
Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

3 Figure 2 LDL-C concentrations vs study time points (on-treatment analysis using raw data). Values at week 12 and week 24 data points indicate achieved LDL-C concentration and LS mean (SE) percent change from baseline. In a post-hoc ITT analysis, the mean (SD) change in LDL-C concentration in the atorvastatin arm was −31.9% (25.1%) at week 24. ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; Pts, patients; SD, standard deviation; SE, standard error. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

4 Figure 3 Distribution by 10-mg/dL increments of LDL-C concentration at baseline and week 24 in patients on alirocumab (left panel) or ezetimibe (right panel; modified ITT population using raw data). Comparison between week 24 and baseline is descriptive and exploratory, as 24-week data were not available for all patients. ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; SE, standard error. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

5 Figure 4 Kaplan–Meier estimates for time to first skeletal muscle–related AE (predefined as myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, or muscle fatigue). AE, adverse event; ALI, alirocumab; ATV, atorvastatin; CI, confidence interval; EZE, ezetimibe; HR, hazard ratio. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

Download ppt "Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial "

Similar presentations

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Volume 26, Issue 2, Pages e2 (August 2017)

Volume 26, Issue 2, Pages e2 (August 2017)
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,
Volume 93, Issue 6, Pages (June 2018)

Volume 93, Issue 6, Pages (June 2018)
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
An assessment by the Statin Diabetes Safety Task Force: 2014 update

An assessment by the Statin Diabetes Safety Task Force: 2014 update
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Similar presentations

Ads by Google